New Compounding Laws Don’t Change FDA Position on Makena

Washington Drug Letter
A A
The FDA does not intend to prevent compounders from making preterm birth drug Makena (hydroxyprogesterone caproate), the agency stated in a legal filing earlier this month that outlines how it intends to approach one contentious issue involving compounders.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00